VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Seven Companies File S-1s in a Single Week
Value Add VC/Pulse/IPO

Seven Companies File S-1s in a Single Week

Seven companies spanning biotech, fintech, AI and battery materials filed IPO registration paperwork with the SEC within days of each other, a broad-based cluster that extends the sustained widening of 2026's listing pipeline.

By the Numbers

7 companies
Filers
July 16, 2026
Filed
Biotech, fintech, AI, materials
Sectors
New + S-1/A amendments
Filing types
TC
By the IPO Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
July 16, 2026
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Elements Ventures Group, iSpecimen (S-1/A), BlossomHill Therapeutics, Artificial Intelligence Technology Solutions, American Battery Materials (S-1/A), SHF Holdings (S-1/A) and Phalanx Acquisition Corp I all filed or amended IPO registration paperwork with the SEC on July 16, per SEC EDGAR filings

2

The mix spans biotech (BlossomHill), specimen and lab logistics (iSpecimen), fintech-adjacent cannabis banking (SHF Holdings), battery materials, a named AI-branded issuer, and a fresh blank-check vehicle in Phalanx -- a genuinely broad cross-section of sectors rather than one dominant theme

3

Several are amendments (S-1/A) rather than first-time filings, indicating companies already deep in the registration process are pushing toward pricing rather than just testing initial investor interest

4

A seven-company cluster in a single week extends the pattern of a widening 2026 listing pipeline across sectors -- SPACs, biotech, battery materials and AI-branded issuers are all represented, not just the mega-cap AI-lab IPOs that dominate most coverage

TC

The VC Read · Trace's Take

Trace Cohen

Seven filings spanning biotech, cannabis banking, battery materials and a fresh SPAC in a single day tells you the listing window is genuinely open across the smaller-cap end of the market, not just for the trillion-dollar AI names getting all the headlines. If you've got a portfolio company sitting on the fence about timing a filing, this is real evidence the SEC review pipeline has capacity and investor appetite exists beyond the mega-cap AI story dominating the news cycle.

Analysis

Seven companies -- Elements Ventures Group, iSpecimen, BlossomHill Therapeutics, Artificial Intelligence Technology Solutions, American Battery Materials, SHF Holdings and a new blank-check vehicle, Phalanx Acquisition Corp I -- all filed or amended IPO registration paperwork with the SEC on July 16, according to SEC EDGAR filings, one of the broader single-day filing clusters of the year.

The mix spans a genuinely wide cross-section of sectors rather than clustering around one dominant theme: BlossomHill Therapeutics represents clinical-stage biotech, iSpecimen operates in lab-specimen and biospecimen logistics, SHF Holdings serves cannabis-industry banking, American Battery Materials sits in the battery-supply-chain space, and Artificial Intelligence Technology Solutions carries an explicitly AI-branded name into the filing queue alongside Phalanx's fresh SPAC vehicle.

“What to watch next: pricing terms and roadshow reception for each of the seven filers, and whether the pace of new filings continues into Q3 or was a one-week cluster.”

Several of the filings are amendments (S-1/A) rather than first-time registrations, meaning those companies are already deep into SEC review and pushing toward an actual pricing date rather than simply testing initial investor interest with a first filing -- a meaningfully more advanced stage of the process than a debut S-1 alone would indicate.

The cluster extends a pattern that's built through 2026: alongside Standard Nuclear's and Csquare's live trading debuts this same week, and Jaguar Health and Vogenx's biotech filings from earlier in July, the IPO pipeline is widening across sectors -- SPACs, biotech, battery materials and AI-branded names are all represented -- rather than remaining concentrated in the mega-cap AI-lab listings that dominate most 2026 IPO coverage.

The bear case: a broad filing cluster doesn't guarantee any of the seven actually prices on favorable terms, and smaller names across biotech, cannabis banking and battery materials have historically faced choppier aftermarket performance than headline tech and AI debuts. What to watch next: pricing terms and roadshow reception for each of the seven filers, and whether the pace of new filings continues into Q3 or was a one-week cluster.

Related Deep Dives

  • ROI of AI in Supply Chain: Real Case Studies and What the... →
  • The IPO Process: From S-1 Filing to First Day of Trading →
  • The Biggest IPO Flops of All Time, Ranked by First-Day an... →
ShareXLinkedInEmail

Key Sources

2 sources
SourceSEC EDGAR
AnalysisValue Add Pulse

Reported by SEC EDGAR · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 31, 2026

The Fall IPO Pipeline, By the Numbers

Illustration for: The Fall IPO Pipeline, By the Numbers
IPO237 IPOs YTD

The Fall IPO Pipeline, By the Numbers

237 IPOs have priced in the US so far in 2026, up 3% from this point last year -- but August was a pause, and the real test is whether Anthropic, DeepSeek, Nscale and Kakao Mobility actually price in the weeks ahead.

IPO· Aug 31, 2026

Salesforce's $5.1B Anthropic Stake Prices Strategic AI Bets

Illustration for: Salesforce's $5.1B Anthropic Stake Prices Strategic AI Bets
IPO$5.1B stake value

Salesforce's $5.1B Anthropic Stake Prices Strategic AI Bets

Salesforce's stock jumped as much as 23% on its own earnings this week, and its Anthropic stake gained $2.6 billion in the process -- the clearest market-priced signal yet of what a strategic bet on a frontier lab is actually worth.

IPO· Aug 31, 2026

Nscale's $51 Billion Number Isn't What It Looks Like

Illustration for: Nscale's $51 Billion Number Isn't What It Looks Like
IPO$51B contracted

Nscale's $51 Billion Number Isn't What It Looks Like

Nscale is telling IPO investors it has $51 billion in contracted revenue -- but that figure counts multi-year compute deals the moment they're signed, and the company's actual annualized run-rate is closer to $400-500 million.

Deep Dives

ROI of AI in Supply Chain: Real Case Studies and What the...The IPO Process: From S-1 Filing to First Day of TradingThe Biggest IPO Flops of All Time, Ranked by First-Day an...
@Trace_Cohen·t@nyvp.com